company background image
VKTX logo

Viking Therapeutics NasdaqCM:VKTX Stock Report

Last Price

US$42.35

Market Cap

US$4.7b

7D

2.1%

1Y

119.8%

Updated

26 Dec, 2024

Data

Company Financials +

Viking Therapeutics, Inc.

NasdaqCM:VKTX Stock Report

Market Cap: US$4.7b

VKTX Stock Overview

A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. More details

VKTX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Viking Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Viking Therapeutics
Historical stock prices
Current Share PriceUS$42.35
52 Week HighUS$99.41
52 Week LowUS$17.23
Beta0.88
1 Month Change-20.72%
3 Month Change-31.28%
1 Year Change119.77%
3 Year Change812.72%
5 Year Change432.70%
Change since IPO372.66%

Recent News & Updates

We're Interested To See How Viking Therapeutics (NASDAQ:VKTX) Uses Its Cash Hoard To Grow

Dec 23
We're Interested To See How Viking Therapeutics (NASDAQ:VKTX) Uses Its Cash Hoard To Grow

Viking Therapeutics: Holiday Gift

Dec 19

Viking Stock Pops, Then Drops On Latest Obesity/MASH Data: Why I'm Still Bullish

Dec 05

Recent updates

We're Interested To See How Viking Therapeutics (NASDAQ:VKTX) Uses Its Cash Hoard To Grow

Dec 23
We're Interested To See How Viking Therapeutics (NASDAQ:VKTX) Uses Its Cash Hoard To Grow

Viking Therapeutics: Holiday Gift

Dec 19

Viking Stock Pops, Then Drops On Latest Obesity/MASH Data: Why I'm Still Bullish

Dec 05

Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations

Nov 04

Viking Therapeutics: Lots Of Positives

Oct 28

Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data

Sep 25

Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Sep 07
Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape

Aug 30

Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands

Jul 25

We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Apr 26
We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Viking Therapeutics: Future Weight Loss Heavyweight?

Apr 02

We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

Jan 09
We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Sep 21
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

Jun 07
Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Mar 05
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics: Playing Second Fiddle To Madrigal

Aug 30

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Jul 13
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Revisiting Viking Therapeutics

Apr 20

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Apr 12
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Dec 17
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Viking Therapeutics: Remaining Bullish And Sticking To My Plan

Aug 27

Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder

Jun 17

Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

Jan 13
Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

Shareholder Returns

VKTXUS BiotechsUS Market
7D2.1%-3.3%-0.4%
1Y119.8%-2.7%24.8%

Return vs Industry: VKTX exceeded the US Biotechs industry which returned -2.7% over the past year.

Return vs Market: VKTX exceeded the US Market which returned 24.8% over the past year.

Price Volatility

Is VKTX's price volatile compared to industry and market?
VKTX volatility
VKTX Average Weekly Movement11.6%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: VKTX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: VKTX's weekly volatility has decreased from 21% to 12% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201231Brian Lianwww.vikingtherapeutics.com

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.

Viking Therapeutics, Inc. Fundamentals Summary

How do Viking Therapeutics's earnings and revenue compare to its market cap?
VKTX fundamental statistics
Market capUS$4.72b
Earnings (TTM)-US$99.15m
Revenue (TTM)n/a

0.0x

P/S Ratio

-47.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VKTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$99.15m
Earnings-US$99.15m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.89
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did VKTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 00:28
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Viking Therapeutics, Inc. is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew LuchiniBMO Capital Markets Equity Research
Mayank MamtaniB. Riley Securities, Inc.
Julian HarrisonBTIG